Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 3, 2020
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharm's Board of...
-
Nov 2, 2020-- Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Unresectable Dedifferentiated Liposarcoma --
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended September 30, 2020....
-
Nov 2, 2020-- Twice-Weekly XPOVIO® (selinexor) Demonstrates a Statistically Significant Reduction in the Risk of Disease Progression or Death Compared to Placebo; Hazard Ratio of 0.70, p=0.023 --
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced positive top-line results from the Phase 3 portion of the...
-
Oct 26, 2020- Conference Call Scheduled for Monday, November 2, 2020, at 4:30 p.m. ET -
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will report third quarter 2020 financial results on...
-
Oct 6, 2020− Encouraging Anti-Viral and Anti-Inflammatory Activity Demonstrated in a Subset of Patients in a Study of Low Dose Selinexor in Hospitalized Patients with Severe COVID-19 −
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced an oral presentation at the International Society for...
-
Oct 1, 2020
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharm's Board of...
-
Sep 14, 2020
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that four abstracts have been selected for poster...
-
Sep 2, 2020
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer of...
-
Sep 1, 2020
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options...
-
Aug 31, 2020− Former Senior Vice President of the Oncology Business Unit at Genentech; Brings Over 25 Years of Extensive Leadership and Commercial Experience in the Pharmaceutical Industry −
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Christy J. Oliger to its Board of...